The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was delighted to speak to Wendy Osborne, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

In this video, Wendy Osborne discusses the Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). She talks about the results from the phase I/II study that assesses the safety and efficacy of this bicistronic approach, which was designed to overcome CD19 escape and CAR T exhaustion.

Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL

Share: